Design Therapeutics, Inc. (DSGN)
- Previous Close
4.5500 - Open
4.6500 - Bid 4.4400 x 100
- Ask 4.5300 x 100
- Day's Range
4.4650 - 4.6800 - 52 Week Range
1.9400 - 8.3100 - Volume
125,297 - Avg. Volume
315,119 - Market Cap (intraday)
257.052M - Beta (5Y Monthly) 1.84
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0400 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.67
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
www.designtx.comRecent News: DSGN
Performance Overview: DSGN
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DSGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DSGN
Valuation Measures
Market Cap
253.66M
Enterprise Value
-14.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.94
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.69%
Return on Equity (ttm)
-20.15%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-58.67M
Diluted EPS (ttm)
-1.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
270.69M
Total Debt/Equity (mrq)
1.07%
Levered Free Cash Flow (ttm)
-32.99M
Research Analysis: DSGN
Company Insights: DSGN
DSGN does not have Company Insights